<DOC>
	<DOCNO>NCT00610246</DOCNO>
	<brief_summary>The purpose study test combination radiation treatment anti-angiogenic drug call sorafenib ( BAY 43-9006 Nexavar ) determine effect combination cancer also side effect radiation treatment . This study also determine high safe dose sorafenib give radiation treatment .</brief_summary>
	<brief_title>A Study Radiation With Sorafenib Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Advanced cancer eligible curative treatment . A measurable lesion thorax , abdomen pelvis . Normal organ bone marrow function . Able receive protocol prescribe radiation . Please refer protocol detail inclusion criterion . Overlap treatment field previous radiation field . Inability meet mandate normal tissue radiation dose constraint . Brain metastasis ( unless previously treat control ) Previous treatment Sorafenib . Poorly control Hypertension . Unable swallow sorafenib tablet . Intercurrent cardiac dysfunction . Uncontrolled intercurrent illness . Please refer protocol detail exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Thorax</keyword>
	<keyword>Abdomen</keyword>
	<keyword>Pelvis</keyword>
	<keyword>Lesion</keyword>
	<keyword>Cancer</keyword>
	<keyword>Radiation</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Advanced Cancer</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Nexavar</keyword>
	<keyword>BAY43-9006</keyword>
</DOC>